Scaling insulin production with Cameron Owen, CEO/co-Founder of rBio

From Lab to Launch by Qualio

It's not hard to find someone who has been affected by diabetes and the rising cost of insulin. In fact, today's guest says that 1 in 10 people in the US today have diabetes and that figure is expected to rise to 1 in 5 by the end of the decade.
That means there's going to be a large increase in the demand of insulin and therefore production.
Cameron Owen co-founder and CEO of rBio joins the show to talk about how rBio is addressing this problem.
rBio is a synthetic biology company developing new strains of microbes to produce insulin at much greater yields than current technology offers. By harnessing these advancements in biology, rBio's mission is to reduce the cost of insulin from the production and supply chain standpoint. Cameron shares his lessons learned from launching rBio just before the pandemic, his thoughts on raising capital, quality management, product development, and his passion for how biology (which he argues is the greatest technology on earth) can solve any problem we face in society today.
His passion and excitement for biotechnology and its applications is contagious.
Show notes

• https://www.rbio.online/
• Email: [e-mail]
• Cameron's LinkedIn: https://www.linkedin.com/company/rbio/

About Cameron:
Cameron Owen is the co-founder of rBio, a synthetic biology company developing new strains of microbes to produce insulin. rBio is harnessing advancements in biology to reduce the cost of insulin, while bringing pharmaceutical supply chains back to the United States.

Music by keldez

Qualio website:
https://www.qualio.com/

Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast

Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8

Music by keldez